Dolutegravir + lamivudine + tenofovir

Description générale

INN	Dolutegravir + lamivudine + tenofovir
Codes ATC	J05AR27
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 2019 (TRS 1021) pour Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
Wikipédia	Dolutegravir + lamivudine + tenofovir
DrugBank	Dolutegravir, Lamivudine, Tenofovir (Tenofovir disoproxil)

Recommandations

Section Fixed-dose combinations of antiretrovirals

- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified